These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21346225)

  • 1. Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?
    Bernstein L; Lacey JV
    J Natl Cancer Inst; 2011 Mar; 103(6):451-3. PubMed ID: 21346225
    [No Abstract]   [Full Text] [Related]  

  • 2. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
    Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
    J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.
    Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
    Cancer Causes Control; 2011 Mar; 22(3):399-405. PubMed ID: 21184265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone status and demographics in early onset breast cancer patients.
    Friend KE; Perry RR; Collins JN; Britt RC; Feliberti EC
    Am Surg; 2012 Jul; 78(7):819-21. PubMed ID: 22748546
    [No Abstract]   [Full Text] [Related]  

  • 6. Is there a role of breast pathologist in diagnostic challenges of discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis?
    Altundag K
    J Neurooncol; 2018 May; 138(1):219. PubMed ID: 29383648
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.
    Ma H; Wang Y; Sullivan-Halley J; Weiss L; Marchbanks PA; Spirtas R; Ursin G; Burkman RT; Simon MS; Malone KE; Strom BL; McDonald JA; Press MF; Bernstein L
    Cancer Res; 2010 Jan; 70(2):575-87. PubMed ID: 20068186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
    Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
    Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
    [No Abstract]   [Full Text] [Related]  

  • 9. Few positives for triple-negative breast cancer.
    Hede K
    J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Howell SJ; Wardley AM; Armstrong AC
    J Natl Cancer Inst; 2009 Dec; 101(24):1730; author reply 1730-1. PubMed ID: 19893007
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinicopathological features of breast cancer with different molecular subtypes in Chinese women.
    Cheng HT; Huang T; Wang W; Yue JQ; Shen N; Guo H; Li DP; Zhao QZ; Yi PF; Wang R; Wang LQ
    J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):117-121. PubMed ID: 23392719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.
    Mittendorf EA; King TA
    Ann Surg Oncol; 2019 May; 26(5):1173-1175. PubMed ID: 30798446
    [No Abstract]   [Full Text] [Related]  

  • 13. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Night work and breast cancer risk defined by human epidermal growth factor receptor-2 (HER2) and hormone receptor status: A population-based case-control study in France.
    Cordina-Duverger E; Koudou Y; Truong T; Arveux P; Kerbrat P; Menegaux F; Guénel P
    Chronobiol Int; 2016; 33(6):783-7. PubMed ID: 27078711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer.
    Sartor H; Zackrisson S; Elebro K; Hartman L; Borgquist S
    Cancer Causes Control; 2015 Jun; 26(6):931-9. PubMed ID: 25860114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinico-morphological significance of spontaneous necrosis in breast cancer].
    Kriuchkov AN
    Vopr Onkol; 2007; 53(2):229-34. PubMed ID: 17663181
    [No Abstract]   [Full Text] [Related]  

  • 17. IMP3 expression in triple-negative breast carcinoma.
    Sidoni A; Cartaginese F
    Hum Pathol; 2010 Sep; 41(9):1355-6; author reply 1356-7. PubMed ID: 20708461
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype.
    Sun X; Nichols HB; Tse CK; Bell MB; Robinson WR; Sherman ME; Olshan AF; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):60-7. PubMed ID: 26545404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
    Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
    Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
    Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
    J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.